You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Creating an sxRNA Organoid Product for Advancing the Study, Prevention and Treatment of Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD)

    SBC: SXRNA TECHNOLOGIES, INC.            Topic: NIA

    Abstract – sxRNA Technologies (sxRNATech) is developing an organoid toolkit for Alzheimer’s Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) that will enable the identification of senescent cells in living tissue providing a novel tool for studying senescence and how it relates to the aging processes while also creating a new platform for high-throughput drug screening in in compl ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. miRNA-Nanotechnology as a novel regenerative therapy for lymphangioleiomyomatosis

    SBC: BIOSPUTNIK LLC            Topic: 172

    ABSTRACT Lymphangioleiomyomatosis (LAM) is a Tuberous sclerosis-related disorder. Both occur due to an inherited or sporadic mutation in either the TSC1 or TSC2 gene, which function as negative regulators of the mTOR pathway. Uncontrolled mTORC1 activity leads to the neoplastic proliferation of abnormal smooth muscle cells (LAM cells) in the lungs, progressive shortness of breath, recurrent pneumo ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. CRISPR-Cas Editing as a Genetic Cure for Autosomal Dominant Polycystic Kidney Disease

    SBC: NEPHROGEN INC.            Topic: 400

    PROJECT SUMMARY Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic disorder in the world and affects 650,000 Americans. ADPKD is caused by mutations in Pkd1 or Pkd2 that trigger proliferation and fluid secretion by renal tubular epithelial cells into cysts, which bilaterally enlarge the kidney and lead to progressive loss of kidney function. There is no cure for ADPK ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Developing a clinical diagnostic tool for age-related cochlear synaptopathy.

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIA

    Age-related hearing loss (ARHL) is the predominant neurodegenerative disease of aging. Recent animal studies have demonstrated that the earliest cochlear pathology due to noise and aging involves a loss of the inner hair cell ribbon synapse. The early consequences of this synaptic loss are not believed to affect hearing sensitivity, but rather, impair speech understanding in background noise. Whil ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. The Assessment of Smart Phone Everyday Tasks (ASSET): A new IADL test for early AD

    SBC: RIP ROAD, INC.            Topic: NIA

    Project SummaryImpairment in instrumental activities of daily living (IADL) is a hallmark of Alzheimer’s disease (AD) dementia and a major source of patient and caregiver burden. Similarly to cognitive changes in AD, subtle difficulties in IADL may begin even before the stage of amnestic mild cognitive impairment (MCI). Recently, greater emphasis has been placed on preclinical AD, which consists ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development and Commercialization of a New Molecularly Targeted Imaging Agent for Multiple Myeloma

    SBC: Sarya, LLC            Topic: 102

    PROJECT SUMMARY Sarya LLC (Sarya) is a nuclear medicine technology company formed to commercialize radiopharmaceuticals. The goal of this Fast-Track STTR is to develop a new specific imaging agent for diagnosis, staging, and treatment of the hematological cancer, multiple myeloma (MM). MM is the 2nd most common blood cancer with an estimated 32,000 new cases and 13,000 deaths per year. Accurate de ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Engineered Biotherapeutic Agent for Treatment of Post-Traumatic Osteoarthritis

    SBC: Provizigen LLC            Topic: NIAMS

    PROJECT SUMMARY/ABSTRACT Post-traumatic osteoarthritis (PTOA) is a degenerative disease of cartilage brought on by traumatic injury to the articular joints. Acute joint injury is followed by severe joint pain and inflammation. This results in much more rapid degeneration of cartilage than in other forms of osteoarthritis, due to the joint instability caused by trauma as well as the increase in pro ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy.

    SBC: Shift Pharmaceuticals Holdings, Inc.            Topic: 106

    Abstract: The objective of this project is to perform the required (and previously approved) IND-enabling experimental work for E1v1.11, a novel drug candidate for Spinal Muscular Atrophy (SMA). SMA is an autosomal recessive disorder that is the leading genetic cause of infantile death worldwide, occurring in ~1:10,000 live births. The gene responsible for SMA is called survival motor neuron-1 (SM ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. A Disease-Modifying Protein Therapeutic for the Treatment of COPD

    SBC: VERRA THERAPEUTICS LLC            Topic: NHLBI

    PROJECT SUMMARY Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide at 3.23 million (2019), while nearly 400 million suffer its effects. COPD is a heterogeneous, multi-phenotypic disease with lung damage derived from smoking, vaping, cooking, forest fires, pollution, chemical exposure, and numerous occupational hazards (e.g., 1st responders, military, agricul ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Carbon Nanotube-Mediated Gene Transfer into Human T-cells for CAR-T HIV Therapy

    SBC: Advanced Gene Transfer Company, Inc.            Topic: 105

    ABSTRACT The HIV pandemic has caused an estimated 33 million deaths to date. In the U.S. alone, 1.2 million people currently live with HIV and 34,800 new cases were diagnosed in 2019. This adds up to an estimated $16.4 billion for a lifetime of HIV treatment for patients in the U.S. HIV infects immune cells which express the CD4 and CXCR4/CCR5 co-receptors including helper T-cells. Even after a pa ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government